NCT03077217 is a Phase 4 clinical trial of Rifaximin in Covert Hepatic Encephalopathy, sponsored by Shanghai Changzheng Hospital.

Who is sponsoring NCT03077217?

NCT03077217 is sponsored by Shanghai Changzheng Hospital.

What drugs are being tested in NCT03077217?

Interventions in NCT03077217: Rifaximin.

What condition does NCT03077217 study?

NCT03077217 studies Covert Hepatic Encephalopathy.

Is NCT03077217 still recruiting?

NCT03077217 is currently completed. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT03077217

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Completed Phase 4 Last updated 1 July 2021

What this trial tests

Phase 4 trial testing Rifaximin in Covert Hepatic Encephalopathy in 40 participants. Completed in 31 May 2020.

Timeline

1 May 2017

Primary endpoint
31 May 2020

31 May 2020

Quick facts

Lead sponsor	Shanghai Changzheng Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 May 2017
Primary completion	31 May 2020
Estimated completion	31 May 2020
Sites	1 location across China

Drugs / interventions tested

Rifaximin (rifaximin) — full drug profile →

Conditions studied

Covert Hepatic Encephalopathy — all drugs for Covert Hepatic Encephalopathy →

Sponsor

Shanghai Changzheng Hospital

Who can join

Adults 18 to 70, any sex, with Covert Hepatic Encephalopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy.
Tan W, Wang J, Shi PM, Feng LM, et al · · 2022 · cited 7× · PMID 36381088 · DOI 10.14218/jcth.2021.00457
Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.
Balzano T. · · 2023 · cited 6× · PMID 36977964 · DOI 10.1007/s11064-023-03916-w

Verify or expand the search:

Other trials of Rifaximin

Trials testing the same drug.

NCT07209371 — Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance · Phase 2 · recruiting
NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
NCT06483737 — Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) · NA · recruiting
NCT06808009 — Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Re · NA · not yet recruiting
NCT06652087 — Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction · NA · recruiting

Other Shanghai Changzheng Hospital trials

Trials by the same sponsor.

NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03077217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03077217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing